NY-PHILIP-MORRIS-INTL

Philip Morris International Inc. (PMI) (NYSE: PM) announced in the 2021 Proxy Statement filed today that its Board of Directors has nominated two new members, Dr. Juan José Daboub and Mr. Shlomo Yanai.

Additionally, Mr. Jacek Olczak has been nominated to the Board following the announcement of his appointment as CEO, a role he will assume immediately following the Annual Shareholders Meeting on May 5.

Dr. Juan José Daboub
Dr. Daboub is an entrepreneurially minded professional who started his career as an engineer before moving into government. In 1999, he was the youngest senior cabinet member in El Salvador, serving first as Chief of Staff to the president and then as Minister of Finance. Later, as a Managing Director at the World Bank Group, he was credited with having driven several corporate initiatives and reforms, including leading the institution’s global agenda on governance and anti-corruption. In the last decade, Dr. Daboub has focused on climate adaptation and energy transition through public and private investment vehicles and not-for-profit organizations, including as Chair of the Council on Climate Change at the World Economic Forum and founding CEO of the Global Adaptation Institute. He is currently President of The Daboub Partnership and of ThinkHUGE USA-Central America Job Creation Council.

Mr. Lucio Noto, PMI’s interim Chairman, welcomed the nomination, saying: “Juan José fully embraces PMI’s commitment to delivering a smoke-free future. Juan José’s experience across multiple business sectors, combined with his deep understanding of geopolitics and international institutions, will be a great addition to the PMI board.”

Dr. Daboub studied industrial engineering at North Carolina State University in the United States, where he earned a bachelor’s degree, a master’s degree, and a PhD.

Mr. Shlomo Yanai
Mr. Yanai was President and CEO of Teva Pharmaceutical Industries from 2007 to 2012. In that time, he led the company’s international expansion and increased annual revenues by nearly USD 10 billion. Prior to that, Mr. Yanai was President and CEO of ADAMA (formerly Makhteshim Agan Industries Ltd.) for three years. His time at those organizations and later as a board member or Chair of several other companies in the pharma space, as well as his current position as Chairman of the Board of Lumenis, a medical devices company, have given Mr. Yanai a solid understanding of the science behind drug discovery, development, and regulation. He also served in the Israeli Defense Forces for more than 30 years, reaching the rank of Major General. In his military career, Mr. Yanai worked extensively with politicians and public sector bodies.

Mr. Noto endorsed the nomination, saying: “The combination of Shlomo’s broad board experience and his knowledge of the pharma industry and its regulatory processes will bring to the Board an extremely relevant set of skills as PMI continues to develop and commercialize scientifically validated smoke-free products and starts deploying its beyond-nicotine strategy.”

Mr. Yanai, a graduate of Harvard Business School’s Advanced Management Program (AMP), holds a BA (cum laude ) in political science and economics from Tel Aviv University and a master’s degree (MPA) in national resources administration from George Washington University. He is also a graduate of the National War College of the U.S. National Defense University.

The nominations announced today follow the appointments of Michel Combes and Bonin Bough to the Board of Directors in December 2020 and February 2021, respectively. Mr. Combes is President of SoftBank Group International and oversees several SoftBank portfolio companies. He was Chief Financial Officer and then CEO and a member of the board of directors of Sprint, CEO of Vodafone Europe, CEO of Alcatel-Lucent, CEO and Chief Operating Officer of Altice, and Chairman and CEO of SFR Group. Prior, he held several positions within French ministries, at France Telecom (including Senior Vice President and Chief Financial Officer) and TDF (Télédiffusion de France). Mr. Bough is the founder and Chief Growth Officer of growth accelerator Bonin Ventures. He has been Chief Growth and Marketing Officer of Sundial Brands (Unilever); Chief Media and E-commerce Officer of Mondelez International; Vice President, Global Media and Consumer Engagement of Kraft Foods Group; and Chief Digital Officer of PepsiCo.

Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships versions of its IQOS Platform 1 device and consumables to Altria Group, Inc. for sale under license in the U.S., where these products have received marketing authorizations from the U.S. Food and Drug Administration (FDA) under the premarket tobacco product application (PMTA) pathway; the FDA has also authorized the marketing of a version of IQOS and its consumables as a modified risk tobacco product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of Dec. 31, 2020, IQOS is available for sale in 64 markets in key cities or nationwide, and PMI estimates that approximately 12.7 million adults around the world have already switched to IQOS and stopped smoking. For more information, please visit www.pmi.com and www.pmiscience.com .

# # #

View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005426/en/